Shocking CFO Departure Sends BDX Stock Tumbling — But Growth Remains Strong
BD said CFO Chris DelOrefice will step down Dec. 5, 2025, with Vitor Roque named interim CFO. Preliminary Q4 revenue rose 8.3% to $5.9 billion, but shares fell 5.8% after hours as U.S. regulators opened a medical-device import probe. FY2025 adjusted EPS is expected at or above guidance midpoint. Analysts’ consensus price target is $205–217.